Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dual antiplatelet therapy with ticagrelor and acetylsalicylic acid (ASA) vs. ASA only after isolated coronary artery bypass grafting in patients with acute coronary syndrome (TACSI trial)

Trial Profile

Dual antiplatelet therapy with ticagrelor and acetylsalicylic acid (ASA) vs. ASA only after isolated coronary artery bypass grafting in patients with acute coronary syndrome (TACSI trial)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 26 Sep 2018

At a glance

  • Drugs Ticagrelor (Primary) ; Aspirin
  • Indications Acute coronary syndromes; Angina pectoris; Myocardial infarction
  • Focus Adverse reactions
  • Acronyms TACSI trial
  • Most Recent Events

    • 18 Sep 2018 Status changed from not yet recruiting to recruiting.
    • 27 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top